[Retinal OCT Biomarkers and Neurodegenerative Diseases of the Central Nervous System Beyond Alzheimer's Disease]

Overview

Journal Ophthalmologie

Specialty Ophthalmology

Date 2024 Jan 24

PMID 38263475

Authors

Susanne Hopf

Oliver Tuscher

Alexander K Schuster

Affiliations

Soon will be listed here.

Abstract

Background: Optical coherence tomography (OCT) biomarkers are increasingly used by neurologists, psychiatrists, and ophthalmologists for the diagnosis, prognosis, and follow-up of neurodegenerative diseases. Long-term data on OCT biomarkers of selected primary and secondary neurodegenerative diseases of the central nervous system (CNS), such as multiple sclerosis (MS) or Parkinson's disease, are already available in part. In addition, there are rare neurodegenerative diseases with early disease onset that may show OCT abnormalities.

Methods: A literature review on the association of OCT biomarkers with neurodegenerative diseases of the CNS beyond Alzheimer's disease is presented. Parkinson's disease, MS, Friedreich's ataxia, Huntington's disease, spinocerebellar ataxia, and lysosomal storage diseases are addressed.

Results: Relevant OCT biomarkers of neurodegenerative diseases are the macular ganglion cell inner plexiform layer (GCIPL) and the peripapillary retinal nerve fiber layer (pRNFL) thickness. Different sectors may be affected depending on the disease entity in addition to global pRFNL reduction. OCT‑angiography (OCT-A) is also increasingly used as a biomarker in neurodegenerative diseases.

Conclusion: Optical coherence tomography biomarkers are used in an interdisciplinary context. Retinal pathologies should be excluded by an ophthalmologist. While OCT biomarkers are increasingly used clinically in MS, the benefit in other neurodegenerative diseases, especially the rare ones, is less well documented. Further longitudinal studies are required.

References

Baldacci F, Mazzucchi S, Della Vecchia A, Giampietri L, Giannini N, Koronyo-Hamaoui M . The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases. Expert Rev Mol Diagn. 2020; 20(4):421-441. PMC: 7445079. DOI: 10.1080/14737159.2020.1731306. View

Malik I, Kelley C, Wang E, Todd P . Molecular mechanisms underlying nucleotide repeat expansion disorders. Nat Rev Mol Cell Biol. 2021; 22(9):589-607. PMC: 9612635. DOI: 10.1038/s41580-021-00382-6. View

Augustin A, Atorf J . The Value of Optical Coherence Tomography Angiography (OCT-A) in Neurological Diseases. Diagnostics (Basel). 2022; 12(2). PMC: 8871393. DOI: 10.3390/diagnostics12020468. View

Aytulun A, Cruz-Herranz A, Aktas O, Balcer L, Balk L, Barboni P . APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies. Neurology. 2021; 97(2):68-79. PMC: 8279566. DOI: 10.1212/WNL.0000000000012125. View

Jonas J, Naumann G . Histomorphometry of the human optic nerve. Invest Ophthalmol Vis Sci. 1990; 31(4):736-44. View

Mardin C . [Optical Coherence Tomography in Glaucomas: Tips and Tricks]. Klin Monbl Augenheilkd. 2020; 237(4):539-551. DOI: 10.1055/a-1098-3466. View

Gmeiner J, Schrems W, Mardin C, Laemmer R, Kruse F, Schrems-Hoesl L . Comparison of Bruch's Membrane Opening Minimum Rim Width and Peripapillary Retinal Nerve Fiber Layer Thickness in Early Glaucoma Assessment. Invest Ophthalmol Vis Sci. 2016; 57(9):OCT575-84. DOI: 10.1167/iovs.15-18906. View

Enders P, Adler W, Schaub F, Hermann M, Dietlein T, Cursiefen C . Novel Bruch's Membrane Opening Minimum Rim Area Equalizes Disc Size Dependency and Offers High Diagnostic Power for Glaucoma. Invest Ophthalmol Vis Sci. 2016; 57(15):6596-6603. DOI: 10.1167/iovs.16-20561. View

Chen Z, Peng P, Shen H, Wei H, Ouyang P, Duan X . Region-segmentation strategy for Bruch's membrane opening detection in spectral domain optical coherence tomography images. Biomed Opt Express. 2019; 10(2):526-538. PMC: 6377878. DOI: 10.1364/BOE.10.000526. View

10.

Petzold A, Fraser C, Abegg M, Alroughani R, Alshowaeir D, Alvarenga R . Diagnosis and classification of optic neuritis. Lancet Neurol. 2022; 21(12):1120-1134. DOI: 10.1016/S1474-4422(22)00200-9. View

11.

London A, Benhar I, Schwartz M . The retina as a window to the brain-from eye research to CNS disorders. Nat Rev Neurol. 2012; 9(1):44-53. DOI: 10.1038/nrneurol.2012.227. View

12.

Lin J, Apte R . Seeing Parkinson Disease in the Retina. JAMA Ophthalmol. 2020; 139(2):189-190. DOI: 10.1001/jamaophthalmol.2020.5719. View

13.

Inzelberg R, Ramirez J, Nisipeanu P, Ophir A . Retinal nerve fiber layer thinning in Parkinson disease. Vision Res. 2004; 44(24):2793-7. DOI: 10.1016/j.visres.2004.06.009. View

14.

Lee J, Ahn J, Kim T, Jeon B . Optical coherence tomography in Parkinson's disease: is the retina a biomarker?. J Parkinsons Dis. 2014; 4(2):197-204. DOI: 10.3233/JPD-130306. View

15.

Huang L, Wang C, Wang W, Wang Y, Zhang R . The specific pattern of retinal nerve fiber layer thinning in Parkinson's disease: a systematic review and meta-analysis. J Neurol. 2020; 268(11):4023-4032. DOI: 10.1007/s00415-020-10094-0. View

16.

Huang L, Zhang D, Ji J, Wang Y, Zhang R . Central retina changes in Parkinson's disease: a systematic review and meta-analysis. J Neurol. 2020; 268(12):4646-4654. DOI: 10.1007/s00415-020-10304-9. View

17.

Zhou W, Tao J, Li J . Optical coherence tomography measurements as potential imaging biomarkers for Parkinson's disease: A systematic review and meta-analysis. Eur J Neurol. 2020; 28(3):763-774. DOI: 10.1111/ene.14613. View

18.

Ortuno-Lizaran I, Sanchez-Saez X, Lax P, Serrano G, Beach T, Adler C . Dopaminergic Retinal Cell Loss and Visual Dysfunction in Parkinson Disease. Ann Neurol. 2020; 88(5):893-906. PMC: 10005860. DOI: 10.1002/ana.25897. View

19.

Lee J, Ahn J, Shin J, Jeon B . Parafoveal Change and Dopamine Loss in the Retina with Parkinson's Disease. Ann Neurol. 2020; 89(2):421-422. DOI: 10.1002/ana.25972. View

20.

Ahn J, Lee J, Kim T, Yoon E, Oh S, Kim Y . Retinal thinning associates with nigral dopaminergic loss in de novo Parkinson disease. Neurology. 2018; 91(11):e1003-e1012. DOI: 10.1212/WNL.0000000000006157. View